ingrid_STO said:Read four things before the headline number.
Saving this. It is the first explanation that did not require me to already understand it.
ingrid_STO said:Read four things before the headline number.
Saving this. It is the first explanation that did not require me to already understand it.
From the other side of the consultation, briefly.
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.
A recent PSM study of 18,000 GLP-1 users vs matched controls showed reduced all-cause mortality (HR 0.81) over 4 years of follow-up[1].
These results complement the RCT data and suggest the benefits translate to real-world populations.
Dr.ObesityLA said:The gap between trial results and real-world results is consistent and it is not fraud.
Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:
The the trial evidence meta-analysis shows a pooled RR of 0.77 (95% CI 0.71-0.82), I²=50%. This is a robust and consistent effect.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAdmin said:The GLP Lounge Community Rules — Updated January 2026 Public Square is a small room with a long memory.
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.
For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."
The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.